EA201791166A1 - Препараты с контролируемым высвобождением - Google Patents

Препараты с контролируемым высвобождением

Info

Publication number
EA201791166A1
EA201791166A1 EA201791166A EA201791166A EA201791166A1 EA 201791166 A1 EA201791166 A1 EA 201791166A1 EA 201791166 A EA201791166 A EA 201791166A EA 201791166 A EA201791166 A EA 201791166A EA 201791166 A1 EA201791166 A1 EA 201791166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
precursor
present
preparation
preparations
liquid
Prior art date
Application number
EA201791166A
Other languages
English (en)
Other versions
EA033590B1 (ru
Inventor
Фредрик Тиберг
Маркус Йонссон
Юстас Бараускас
Original Assignee
Камурус Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Камурус Аб filed Critical Камурус Аб
Publication of EA201791166A1 publication Critical patent/EA201791166A1/ru
Publication of EA033590B1 publication Critical patent/EA033590B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к составам для получения лекарственной формы, содержащим имеющие низкую вязкость нежидкокристаллические смеси: a) по меньшей мере одного сложного эфира сахара или производного сахара; b) по меньшей мере одного фосфолипида; c) по меньшей мере одного биосовместимого кислородсодержащего имеющего низкую вязкость органического растворителя; причем указанный препарат-предшественник образует или способен образовывать по меньшей мере одну структуру жидкокристаллической фазы при контакте с водной жидкостью, при условии, что указанный препарат-предшественник не содержит дополнительно отвердитель жидких кристаллов. Указанные препараты-предшественники подходят для получения вводимых парентерально, не парентерально и топически депо-композиций для пролонгированного высвобождения активных агентов. Настоящее изобретение дополнительно относится к способу доставки активного агента, включающему введение препарата-предшественника согласно настоящему изобретению, депо-композиции, образующейся в результате контакта препаратов-предшественников согласно настоящему изобретению с водной жидкостью, способу лечения, включающему введение препарата-предшественника согласно настоящему изобретению, и применению препарата-предшественника согласно настоящему изобретению.
EA201791166A 2014-12-23 2015-12-23 Препараты с контролируемым высвобождением EA033590B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201423134 2014-12-23
PCT/EP2015/081191 WO2016102683A1 (en) 2014-12-23 2015-12-23 Controlled-release formulations

Publications (2)

Publication Number Publication Date
EA201791166A1 true EA201791166A1 (ru) 2017-12-29
EA033590B1 EA033590B1 (ru) 2019-11-07

Family

ID=55071020

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791166A EA033590B1 (ru) 2014-12-23 2015-12-23 Препараты с контролируемым высвобождением

Country Status (13)

Country Link
US (2) US20180000943A1 (ru)
EP (1) EP3236937B1 (ru)
JP (1) JP6822962B2 (ru)
KR (1) KR20170099978A (ru)
CN (1) CN107257681A (ru)
AU (1) AU2015370922B2 (ru)
BR (1) BR112017013471A2 (ru)
CA (1) CA2971642A1 (ru)
EA (1) EA033590B1 (ru)
IL (1) IL253042B (ru)
SG (1) SG11201705155SA (ru)
WO (1) WO2016102683A1 (ru)
ZA (1) ZA201704263B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
CN109789215B (zh) 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107049932B (zh) * 2017-06-22 2020-11-06 四川大学 一种小分子药物原位相变凝胶缓释系统及其制备方法
CN112188898A (zh) * 2017-11-15 2021-01-05 节奏制药公司 缓释肽配制品
CN112955181A (zh) * 2019-03-26 2021-06-11 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
CN111643483B (zh) * 2020-07-06 2022-03-29 济南大学 一种用于制备加兰他敏缓释微球的方法
CN117794519A (zh) 2021-07-27 2024-03-29 法纳克斯株式会社 非层状液晶形成性组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
WO2013030838A2 (en) * 2011-08-29 2013-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dendrimer-lyotropic liquid crystal (llc) systems
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
BR112014013693B1 (pt) * 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
GB201205642D0 (en) * 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN107257681A (zh) 2017-10-17
EP3236937B1 (en) 2022-05-04
BR112017013471A2 (pt) 2018-02-27
EP3236937A1 (en) 2017-11-01
IL253042A0 (en) 2017-08-31
NZ732827A (en) 2023-11-24
AU2015370922B2 (en) 2018-10-04
CA2971642A1 (en) 2016-06-30
JP6822962B2 (ja) 2021-01-27
JP2018502091A (ja) 2018-01-25
KR20170099978A (ko) 2017-09-01
SG11201705155SA (en) 2017-07-28
WO2016102683A1 (en) 2016-06-30
AU2015370922A1 (en) 2017-07-06
ZA201704263B (en) 2019-09-25
US20180000943A1 (en) 2018-01-04
US20200353086A1 (en) 2020-11-12
IL253042B (en) 2020-08-31
EA033590B1 (ru) 2019-11-07

Similar Documents

Publication Publication Date Title
EA201791166A1 (ru) Препараты с контролируемым высвобождением
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201491005A1 (ru) Устойчивые составы с контролируемым высвобождением
EA201890573A1 (ru) Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5
MY177820A (en) Controlled release peptide formulations
EA201792421A1 (ru) Амидозамещенные производные циклогексана
AR105493A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
BR112016001948A2 (pt) antagonistas de v1a para tratar distúrbios do sono de desvio de fase
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
CL2016003063A1 (es) Composición basada en una solución estabilizada de ingredientes activos
MX2019002999A (es) Formulaciones de analogo de prostaciclina.
EA201690626A1 (ru) Новый состав гонадотропинов
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета
CO2018000526A2 (es) Concentrado que contiene alprostadil
PE20171305A1 (es) Formulaciones inyectables de paracetamol
CO2018000525A2 (es) Concentrado que contiene alprostadil
TH167877B (th) สูตรผสมใหม่สำหรับโกนาโดโทรพิน
TH167877A (th) สูตรผสมใหม่สำหรับโกนาโดโทรพิน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM